HC Wainwright Reaffirms Buy Rating for Axovant Sciences (AXON)
Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Friday. They currently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 105.80% from the company’s previous close.
AXON has been the subject of several other research reports. BidaskClub lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. Jefferies Group set a $40.00 price objective on Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. Oppenheimer reiterated a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Evercore ISI restated an “outperform” rating and set a $9.00 price target (down from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Finally, ValuEngine downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $14.13.
Shares of Axovant Sciences (AXON) traded down $0.17 during trading on Friday, reaching $5.35. The company’s stock had a trading volume of 523,375 shares, compared to its average volume of 1,019,414. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a fifty-two week low of $4.60 and a fifty-two week high of $27.98.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after acquiring an additional 6,558,462 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Axovant Sciences during the 2nd quarter worth approximately $47,854,000. OxFORD Asset Management LLP increased its position in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Capital Research Global Investors increased its position in shares of Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new position in shares of Axovant Sciences during the 3rd quarter valued at approximately $4,471,000. 96.93% of the stock is currently owned by institutional investors.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.